RHEUMATOLOGY GRAND ROUNDS

*Presented by*

Yale School of Medicine’s, Department of Internal Medicine,

Section of Rheumatology

**“Management of Antiphospholipid Syndrome”**

**Yu Pei Eugenia Chock, MD, MPH**

Instructor, Section of Rheumatology

**Date: Wednesday, October 23, 2019**

**Location: 300 Cedar St., TAC Building Room N-203**

**Time: 8:00-9:00 am**

**Course Director/Host: Fotios Koumpouras, MD**

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

**NEEDS ASSESSMENT**

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic or obstetrical events that occur in patients with persistent antiphospholipid antibodies. Although criteria for classification of APS have been proposed, the definition of clinically significant antiphospholipid (aPL) antibody positivity is not well established. This talk will review the classification criteria, clinical significance, and testing of aPL’s, as well as discuss current available therapeutic options and recommendations for primary and secondary prophylaxis in at-risk patients.

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Review classification criteria, testing of aPLs
2. Clinical significance of aPL risk profiles
3. Primary and Secondary Thrombosis Prevention in patients with aPL positivity and APS
4. Review Current therapeutic options

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

*Speaker:* Yu Pei Chock, MD – NONE

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.